Stockwatch: Regeneron Failure Could Hurt Rivals More

A Friday morning clinical trial result at Regeneron had implications across a large number of companies marketing and developing ant-VEGF and anti-PDGF drugs including Ophthotech, Allergan, Roche and Novartis.